|
Daehan New Pharm filed two patent applications, including for a hypertension treatment
2009.07.29
|
|---|
|
Daehan New Pharm announced on July 29 that it had filed two patents, including one for the antihypertensive drug lacidipine.
Lacidipine is an antihypertensive that is taken once a day, convenient to take, and has low tolerance. It is exclusively sold in Korea by the foreign company GlaxoSmithKline (GSK) with annual sales of about 20 billion won. Daehan New Pharm has completed the bioequivalence test for lacidipine and plans to launch it in November 2009. Daehan New Pharm expects to capture 25% of the lacidipine formulation market in 2010, expecting additional sales of around 5 billion won.
Daehan New Pharm has also developed and launched "Stopping," a preventative and adjunctive treatment for pig diarrhea, which is a fatal disease in pigs, and has completed a patent application for this treatment adjunct.
The market for preventative and adjunctive pig diarrhea treatments for pig farms is estimated to be about 10 billion won, and it is expected that exclusive supply will be possible in the domestic market, where there are currently no specific pig diarrhea adjunctive treatments. |


Home